Funding scheme:

FP7-PEOPLE-2010-ITN – Grant Agreement ID 264817

Time frame:

1 February 2011 to 31 January 2015

Weblink:

http://www.bonenet.eu/
CORDIS: https://cordis.europa.eu/project/id/264817

Description:

Bone is often a metastatic site for many types of cancer, indicating that it constitutes an attractive microenvironment for the migration and growth of cancer cells. In addition, bone can be the primary location for osteosarcoma development. To tackle cancer cell dissemination to the bone, one needs to understand the mechanism by which such cells migrate. The scope of the BONE-NET project was to investigate early molecular mechanisms associated with cancer metastases and identify genes and their regulators that attract cancer cells to the bone. Ultimately, the goal was to develop targeted therapies and discover novel diagnostic biomarkers. The consortium recruited early-stage and experienced researchers and trained them in proteomics and functional genomics, gene therapy as well as the development of novel pharmacological therapies. GenomeScan led the training of an experienced researcher (ER) fellow, coordinated a workshop on Advanced Genomics, performed Single Cell RNA Sequencing (scRNAseq) experiments and coordinated the bioinformatic analysis of the generated data.

Output:

CRIPTO and its signalling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer. Zoni E, et al. Oncogene 36, 4739–4749 (2017). doi: 10.1038/onc.2017.87

Acknowledgements:

This project has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement No 264817.